Pharmacokinetics and therapeutic efficacy of amikacin given by intravenous drip infusion in cases of respiratory infection

Akira Watanabe, Kotaro Oizumi, Kiyoshi Konno

    研究成果: Article査読

    抄録

    In 8 patients with respiratory tract infection, the pharmacokinetics of amikacin, including its sputum level in one patient, were studied after a 60-minute intravenous infusion of 100 mg of amikacin. Also, therapeutic effects of amikacin combined with new cephems were evaluated in these patients. The concentrations of amikacin in serum and sputum were measured by fluorescence polarization immunoassay (FPIA) and bioassay, respectively. The serum concentration ranged from 6.10∼41.49μg/ml (mean±standard deviation [SD], 8.29±1.8) and was highest at the end of the infusion. After 30, 60, 120, 240 and 360 minutes, the serum concentration was 3.06∼4.66 (mean±SD, 5.24±1.2 μ/ml), 2.12∼5.41 (3.92±1.0), 1.02∼3.86 (2.87±0.9), 0.23∼2.11 (1.41±0.8) and 0.05∼1.46μg/ml (0.75±0.4), respectively. The half-life of amikacin was 2.20±0.79 h. The highest concentration of amikacin in sputum from one patient was 3.43μg/ml, which occurred 1 h after the end of the infusion. The maximum penetration rate of amikacin from serum to sputum was 37.7%. The therapeutic efficacy of amikacin combined with new cephems was excellent in 1 patient and good in 7 patients. No adverse reactions were observed during or after treatment. We conclude that the intravenous drip infusion of amikacin is useful and safe in the treatment of respiratory infections.

    本文言語English
    ページ(範囲)304-309
    ページ数6
    ジャーナルChemotherapy
    36
    4
    DOI
    出版ステータスPublished - 1988 1月 1

    ASJC Scopus subject areas

    • 薬理学(医学)
    • 感染症
    • 薬理学
    • 創薬
    • 腫瘍学

    フィンガープリント

    「Pharmacokinetics and therapeutic efficacy of amikacin given by intravenous drip infusion in cases of respiratory infection」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

    引用スタイル